Form 4 for ORKA Oruka Therapeutics, Inc.
Accepted 2026-05-22 16:54:18 ET · period of report 2026-05-21 · accession 0000907654-26-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-05-22 16:54 | 2026-05-21 | ORKA | Dambkowski Carl | Dir | M - OptEx | $7.95 | +62.3K | 178.7K | +53% | +$494.8K |
| DMT | 2026-05-22 16:54 | 2026-05-21 | ORKA | Dambkowski Carl | Dir | S - Sale+OE | $58.97 | -105.0K | 73.7K | -59% | -$6.19M |
| DMT | 2026-05-22 16:54 | 2026-05-21 | ORKA | Dambkowski Carl | Dir | M - OptEx | $0.00 | -62.3K | 5,833 | -91% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-21 | M | A | 38,689 | $6.84 | 155,172 | D | — | — | |
| 2 | Common | Common Stock | 2026-05-21 | M | A | 11,904 | $7.80 | 167,076 | D | — | — | |
| 3 | Common | Common Stock | 2026-05-21 | M | A | 11,667 | $11.77 | 178,743 | D | — | — | |
| 4 | Common | Common Stock | 2026-05-21 | S | D | 38,318 | $58.43 | 140,425 | D | — | — | (F1) These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.71 to $58.70, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. |
| 5 | Common | Common Stock | 2026-05-21 | S | D | 53,447 | $59.10 | 86,978 | D | — | — | (F1) These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.71 to $59.70, inclusive. |
| 6 | Common | Common Stock | 2026-05-21 | S | D | 13,235 | $59.97 | 73,743 | D | — | — | (F1) These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.71 to $60.31, inclusive. |
| 7 | Derivative | Stock Option (right to buy) | 2026-05-21 | M | D | 38,689 | $0.00 | 32,737 | D | $6.84 · — to 2034-05-06 | 38,689 Common Stock | (F5) The option vests as to 25% of the shares underlying the option on March 1, 2025, and as to 1/48 of the shares underlying the option monthly thereafter. |
| 8 | Derivative | Warrant (right to buy) | 2026-05-21 | M | D | 11,904 | $0.00 | 10,952 | D | $7.80 · — to 2034-07-14 | 11,904 Common Stock | (F6) The option vests as to 25% of the shares underlying the option on April 3, 2025, and as to 1/48 of the shares underlying the option monthly thereafter. |
| 9 | Derivative | Stock Option (right to buy) | 2026-05-21 | M | D | 11,667 | $0.00 | 5,833 | D | $11.77 · — to 2035-06-01 | 11,667 Common Stock | (F7) The option vests as to 1/12 of the shares underlying the option monthly from June 2, 2025. |